← Back to Search

CAR T-cell Therapy

CATCH T Cells for Solid Cancers

Phase 1
Recruiting
Led By Tannaz Armaghany, MD
Research Sponsored by Baylor College of Medicine
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Lansky or Karnofsky score ≥ 60%
platelet count > 25,000/μl (can be transfused)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 15 years
Awards & highlights

Study Summary

This trial is testing a new way to fight cancer by genetically engineering patients' T cells to better target and kill their tumor cells.

Who is the study for?
Adults with certain solid tumors like liver cancer, who have tried standard treatments without success or can't receive them. They must be in relatively good health with a life expectancy of at least 12 weeks and adequate organ function. Pregnant individuals, those with HIV, active infections (except Hepatitis B/C), or history of organ transplant cannot participate.Check my eligibility
What is being tested?
The trial is testing CATCH T cells, which are the patient's own immune cells genetically modified to target and kill cancer cells by recognizing a protein called GPC3 on tumor surfaces. The study aims to determine the highest safe dose, how long these cells last in the body, their side effects, and effectiveness against GPC3-positive tumors.See study design
What are the potential side effects?
Potential side effects include reactions related to immune response such as fever or fatigue; risk of infection; possible damage to non-cancerous tissues that also carry the GPC3 protein; and other unforeseen complications due to genetic modification of T cells.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I can care for myself but may need occasional help.
Select...
My platelet count is above 25,000, or I can receive a transfusion to reach it.
Select...
I can care for myself but may need occasional help.
Select...
My kidneys are functioning well, with a creatinine clearance rate of 60 ml/min or higher.
Select...
My liver is functioning well enough for treatment.
Select...
My condition did not improve after initial and at least one follow-up treatment.
Select...
I am 18 years old or older.
Select...
My tumor is GPC3-positive and has relapsed or is not responding to treatment.
Select...
I am 18 years old or older.
Select...
I have recovered from the side effects of my previous cancer treatments.
Select...
My bilirubin levels are less than three times the upper limit.
Select...
My liver cancer is at an early to intermediate stage.
Select...
My liver is functioning well enough for treatment.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~15 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 15 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of Patients with Dose Limiting Toxicity
Secondary outcome measures
Median T cell persistence
Percent of Patients with best response as either complete response or partial response

Trial Design

1Treatment groups
Experimental Treatment
Group I: CATCH T cellsExperimental Treatment1 Intervention
GPC3-CAR and the IL15 (CATCH T cells) will be administered to patients with GPC3-positive solid tumors.

Find a Location

Who is running the clinical trial?

Baylor College of MedicineLead Sponsor
1,001 Previous Clinical Trials
6,002,225 Total Patients Enrolled
3 Trials studying Wilms Tumor
69 Patients Enrolled for Wilms Tumor
The Methodist Hospital Research InstituteOTHER
271 Previous Clinical Trials
80,348 Total Patients Enrolled
Center for Cell and Gene Therapy, Baylor College of MedicineOTHER
111 Previous Clinical Trials
2,790 Total Patients Enrolled
3 Trials studying Wilms Tumor
69 Patients Enrolled for Wilms Tumor

Media Library

CATCH T cells (CAR T-cell Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT05103631 — Phase 1
Wilms Tumor Research Study Groups: CATCH T cells
Wilms Tumor Clinical Trial 2023: CATCH T cells Highlights & Side Effects. Trial Name: NCT05103631 — Phase 1
CATCH T cells (CAR T-cell Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05103631 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is there still room for participants in this experiment?

"Affirmative. According to the data hosted on clinicaltrials.gov, this ongoing medical trial is actively recruiting participants since its posting date of June 17th 2021 and its last edit was made on January 2nd 2022. The study requires 27 patients from a single site."

Answered by AI

What health conditions typically benefit from CATCH T cell treatments?

"CATCH T cells have been used to treat a range of conditions, including multiple sclerosis and various forms of lymphoma, leukemia, myelocytic disorder or acute retinoblastoma."

Answered by AI

What is the upper limit of participants in this trial?

"Indeed, clinicaltrials.gov shows that this research is still recruiting participants; it was posted on June 17th 2021 and its details were revised as recently as January 2nd 2022. The study requires 27 individuals to be enrolled across 1 centre."

Answered by AI

What other exploratory tests have been conducted using CATCH T cells?

"Research into CATCH T cells is currently booming with 889 clinical trials in progress. Over a sixth of these are in the advanced stage 3, and 28443 different medical centres across the world are hosting related studies. The primary hub for this research is located in Philadelphia, Pennsylvania."

Answered by AI

Are there any potential hazards associated with CATCH T cells treatment?

"The safety of CATCH T cells is scored at 1, as it has yet to undergo significant testing for both efficacy and safety."

Answered by AI

Who else is applying?

What state do they live in?
Washington
What site did they apply to?
Houston Methodist Hospital
What portion of applicants met pre-screening criteria?
Did not meet criteria
How many prior treatments have patients received?
0
Recent research and studies
clinicaltrials.govStudy
Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors
Tannaz Armaghnay 2021. "Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05103631.
All > Rhabdomyosarcoma
~5 spots leftby Jan 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top